RxDoctor Payments Data

Aremmia Tanious, MD

Neurology · Laurel, MSNPI 1184638033

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $36,325 of the $52,576 with a category attached, or 69.1%. AbbVie accounts for 75.3% of it on its own, with 59 other manufacturers making up the rest. Among neurology clinicians in MS with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$52,576in general payments, 2019–2025

Across 883 payments — averaging $59.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$40K
  • Acadia Pharmaceuticals Inc$1K
  • SK Life Science, Inc.$1K
  • Pfizer$871
  • Lilly USA, LLC$751
  • Teva Pharmaceuticals USA, Inc.$644
  • plus $9K from 54 others

What the payments were for

  • Speaking & faculty fees$36,32569%
  • Travel & lodging$8362%
  • Food & beverage$15,37729%
  • Education$380%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)162$39,609
Acadia Pharmaceuticals Inc61$1,097
SK Life Science, Inc.54$1,086
Pfizer55$871
Lilly USA, LLC55$751
Teva Pharmaceuticals USA, Inc.41$644
Sunovion Pharmaceuticals Inc.36$538
UCB, Inc.27$510
ANI Pharmaceuticals, Inc.9$493
Eisai Inc.21$412
Upsher-smith Laboratories LLC26$390
Takeda Pharmaceuticals U.S.A., Inc.22$372
Otsuka America Pharmaceutical, Inc.15$357
Octapharma USA, Inc.16$344
Adamas Pharmaceuticals, Inc.17$320
Sanofi17$282
Supernus Pharmaceuticals, Inc.17$279
Novartis16$268
Johnson & Johnson(2 entities)14$259
Biohaven Pharmaceuticals, Inc.14$246
Argenx US, Inc.12$239
Amgen14$230
Avanir Pharmaceuticals, Inc.16$212
Lundbeck LLC13$210
Harmony Biosciences LLC8$206
Biohaven Pharmaceutical Holding Company Ltd.11$205
GE HealthCare10$193
Sumitomo Pharma America, Inc.9$174
Neurocrine Biosciences, Inc.8$153
Neuronetics, Inc.5$152
Biogen8$132
Inspire Medical Systems, Inc.4$131
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC8$121
AstraZeneca7$117
Idorsia Pharmaceuticals US Inc5$92
MDD US Operations, LLC5$86
Jazz Pharmaceuticals Inc.4$73
Corium, LLC4$72
Catalyst Pharmaceuticals, Inc.4$71
Genentech USA, Inc.4$67
Valinor Pharma, LLC4$67
Neurelis, Inc.2$52
Vanda Pharmaceuticals Inc.3$47
Axsome Therapeutics, Inc.2$45
Shire North American Group Inc3$43
Itamar Medical Inc1$34
Alkermes, Inc.1$24
Averitas Pharma Inc.1$20
Merz Pharmaceuticals, LLC1$19
Impel Pharmaceuticals Inc.1$17
Kowa Pharmaceuticals America, Inc.1$17
Greenwich Biosciences, Inc.1$16
Scilex Pharmaceuticals Inc.1$16
E.r. Squibb & Sons, L.L.C.1$15
GRT US Holding, Inc.1$15
Medtronic1$14
Vertos Medical, Inc.1$14
Merck1$14
Arbor Pharmaceuticals, Inc.1$13
Sanofi-aventis U.S. LLC1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$52,576 in reported general payments places this provider in the 90th percentile of 111 neurology providers in Mississippi.

See all neurology providers in Mississippi

Medicare billing

Part B allowed, 2024
$209,941
Medicare patients
578
Services billed
5,678

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen332$5,097
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen365$4,755
Dimethyl Fumarate14$3,125
Duloxetine Hcl307$2,626
Levetiracetam183$2,595
Gabapentin330$2,387
Diclofenac Sodium146$1,784
Carbidopa-LevodopaCarbidopa/Levodopa97$1,504
Oxycodone Hcl84$1,484
Phenytoin Sodium Extended67$1,478
Amitriptyline Hcl209$1,251
Quetiapine Fumarate152$1,168
Aripiprazole15$1,114
Sumatriptan Succinate17$1,001
Primidone83$987

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Upsher-smith Laboratories LLCTopiramate$390$899120 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 111 neurology providers in Mississippi.

Other neurology in Laurel

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →